bler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 2018; 19: 33–50. 3 Schluter J, Peled JU, Taylor BP et al. The gut microbiota is associated with immune cell dynamics in humans. Nature 2020; 588: 303–307. 4 Santos ESP, Bennett CL, Chakraverty R. Unraveling the mechanisms of cutaneous graft-versus-host disease. Front Immunol 2018; 9: 963. 5 Gu Y, Sun J, Li K, Wu X, Zhang J. Alteration in the skin microbiome in cutaneous graft versus host disease. Acta Derm Venereol 2021; 101: adv00374. 6 Shimizu E, Ogawa Y, Saijo Y et al. Commensal microflora in human conjunctiva; characteristics of microflora in the patients with chronic ocular graft-versus-host disease. Ocul Surf 2019; 17: 265–271. 7 Gavriilaki M, Sakellari I, Anagnostopoulos A, Gavriilaki E. The Impact of antibiotic-mediated modification of the intestinal microbiome on outcomes of allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Biol Blood Marrow Transplant 2020; 26: 1738– 1746. 8 Parco S, Benericetti G, Vascotto F, Palmisciano G. Microbiome and diversity indices during blood stem cells transplantation new perspectives? Cent Eur J Public Health 2019; 27: 335–339. 9 Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv 2018; 2: 3411–3417. 10 Saidu NEB, Bonini C, Dickinson A et al. New approaches for the treatment of chronic graft-versus-host disease: current status and future directions. Front Immunol 2020; 11: 578314. 11 Kumari R, Palaniyandi S, Hildebrandt GC. Microbiome: an emerging new frontier in graft-versus-host disease. Dig Dis Sci 2019; 64: 669– 677. 12 Johnson ME, Franks JM, Cai G et al. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Res Ther 2019; 21: 49. 13 Ganju P, Nagpal S, Mohammed MH et al. Microbial community profiling shows dysbiosis in the lesional skin of Vitiligo subjects. Sci Rep 2016; 6: 18761. 14 O’Leary OE, Schoetzau A, Amruthalingam L et al. Tear proteomic predictive biomarker model for ocular graft versus host disease classification. Transl Vis Sci Technol 2020; 9: 3.
[1]
M. Esposito,et al.
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24‐week real‐life experience
,
2021,
Dermatologic therapy.
[2]
J. Dauendorffer,et al.
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate‐to‐severe genital psoriasis
,
2020,
Journal of the European Academy of Dermatology and Venereology : JEADV.
[3]
J. Erickson,et al.
Ixekizumab Results in Persistent Clinical Improvement in Moderateto-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial
,
2020,
Acta dermato-venereologica.
[4]
A. Gottlieb,et al.
Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis
,
2018,
The British journal of dermatology.
[5]
A. Menter,et al.
Genital psoriasis is associated with significant impairment in quality of life and sexual functioning.
,
2015,
Journal of the American Academy of Dermatology.